To date, one study is currently testing the feasibility, safety, and efficacy of multiple fourth generation CAR-T cells targeting Her2, GD2, and CD44v6 surface antigen in BC (NCT04430595), but no results have been published yet. Here, ERBB2 is linked to breast cancer.